Changes of Blood-Brain Barrier and Brain Parenchymal Protein Expression Levels of Mice under Different Insulin-Resistance Conditions Induced by High-Fat Diet
The purpose of the present study was to investigate changes of blood-brain barrier (BBB) and brain parenchymal protein expression due to type II diabetes mellitus (T2DM) induced by a high-fat diet (HFD) by using SWATH-based quantitative proteomics.
Mice were fed a HFD for 2 or 10 weeks, and then SWATH-based quantitative proteomic analysis, western blot analysis, immunohistochemistry and functional transport studies were performed.
In brain capillaries, expression levels of BBB transporters (Glut1, P-glycoprotein) and tight-junction proteins (claudin-5, occludin) were significantly reduced in HFD mice at 2 weeks, but recovered to the levels in the normal diet (ND) group at 10 weeks. P-glycoprotein function at the BBB was reduced at 2 weeks. In the cerebral cortex and hippocampus, neurofilament, which is important for neuronal function, was decreased in HFD mice at 2 weeks, but recovered at 10 weeks.
Our results suggest that changes in the status of insulin resistance influence expression of BBB transporters, which in turn may alter the expression of cognitive function-related proteins.
Key WordsBlood-brain barrier central nervous system insulin resistance quantitative proteomics type II diabetes mellitus
Amyloid β peptide
Ca2+/calmodulin-dependent protein kinase
Central nervous system
Glucose transporter 1
human cerebral vascular endothelial cell
Large neutral amino acids transporter small subunit 1
Low density lipoprotein receptor-related protein 1
Monocarboxylate transporter 1
Multidrug resistance protein 1a
Phosphate buffered saline
Post synaptic density
Reactive oxygen species
Sequential window acquisition of all theoretical fragment-ion spectra
Type 2 diabetes mellitus
Tumor necrosis factor-alpha
Vascular endothelial growth factor
Acknowledgments and Disclosures
We are grateful for partial financial support in the form of three Grants-in-Aid for Scientific Research from the Japanese Society for the Promotion of Science (JSPS) and a Grant-in-Aid for Scientific Research on Innovative Areas (15H01562), as well as a grant from the Mochida Memorial Foundation for Medical and Pharmaceutical Research. Ohtsuki S is a full professor at Kumamoto University and is also a director of Proteomedix Frontiers. This study was not supported by the company, and his position at the company did not influence the design of the study, the collection of the data, the analysis or interpretation of the data, the decision to submit the manuscript for publication, or the writing of the manuscript, and did not present any financial conflicts. The other authors declare no competing interests.
All authors, Ogata S, Ito S, Masuda T and Ohtsuki S, contributed to study design and manuscript revision. Ogata S conducted experiments and performed data analysis. Ogata S, Ito S. and Ohtsuki S wrote the manuscript. All authors provided final approval of the submitted manuscript.
- 14.Uchida Y, Tachikawa M, Obuchi W, Hoshi Y, Tomioka Y, Ohtsuki S, et al. A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS. 2013;10(1):21.PubMedPubMedCentralCrossRefGoogle Scholar
- 16.Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther. 2011;339(2):579–88.PubMedCrossRefGoogle Scholar
- 20.Di Domenico F, Owen JB, Sultana R, Sowell RA, Perluigi M, Cini C, et al. The wheat germ agglutinin-fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: implications for disease pathogenesis and progression. J Neurosci Res. 2010;88(16):3566–77.PubMedCrossRefGoogle Scholar
- 21.Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, et al. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis. 2008;30(1):107–20.PubMedCrossRefGoogle Scholar
- 23.Roberts EL. 2.1 The support of energy metabolism in the central nervous system with substrates other than glucose. In: Lajtha A, Gibson GE, Dienel GA (eds). Handbook of Neurochemistry and Molecular Neurobiology: Brain Energetics. Integration of Molecular and Cellular Processes. Springer US: Boston, MA, 2007, pp 137–179.CrossRefGoogle Scholar
- 27.Greene C, Kealy J, Humphries MM, Gong Y, Hou J, Hudson N, et al. Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia. Mol Psychiatry. 2017.Google Scholar